---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-033771"
form_type: "8-K/A"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2026-02-02T23:59:59+00:00"
generated_at: "2026-05-16T05:50:07.203746+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# XOMA completes acquisition of LAVA legacy assets; details Pfizer, Janssen programs and CVR terms

## Summary
- XOMA completed acquisition of LAVA legacy assets (EGFRd2, JNJ-89853413, LAVA-1266) on Nov 20, 2025.
- EGFRd2 (PF-8046052) outlicensed to Pfizer; potential milestones up to ~$650M; Phase 1 trial expected to complete 2029/2030.
- JNJ-89853413 outlicensed to Janssen; potential milestones up to ~$195M; Phase 1 started Jan 2025, expected completion Aug 2028.
- CVRs issued for 75% of net proceeds from future asset sales; XOMA valued CVRs at $0.00 due to early-stage uncertainty.
- XOMA will use commercially reasonable efforts for 2 years to sell or license the legacy assets for CVR holders.

## SEC filing metadata
- accession: 0001193125-26-033771
- form_type: 8-K/A
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2026-02-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312526033771/0001193125-26-033771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312526033771/d135386d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-033771
- JSON: https://secwatch.observer/filing/0001193125-26-033771.json
- Plain text: https://secwatch.observer/filing/0001193125-26-033771.txt

## Source-grounded claims
- claim_id: a859a5056e862c35b86c20e6be11edc85a5e4ee2
  claim: XOMA Royalty Corp completed an acquisition involving LAVA Therapeutics N.V. (closed 2025-11-20).
  evidence_excerpt: XOMA acquired LAVA's EGFRd2 (PF-8046052), JNJ-89853413 and LAVA-1266 legacy assets
  evidence_url: https://www.sec.gov/Archives/edgar/data/791908/000119312526033771/0001193125-26-033771-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.